Compare SJM & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SJM | MEDP |
|---|---|---|
| Founded | 1897 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.9B |
| IPO Year | 1994 | 2016 |
| Metric | SJM | MEDP |
|---|---|---|
| Price | $106.44 | $449.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 13 |
| Target Price | $120.50 | ★ $498.25 |
| AVG Volume (30 Days) | ★ 2.0M | 368.0K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 15.28 |
| Revenue | ★ $8,726,100,000.00 | N/A |
| Revenue This Year | $4.81 | $13.11 |
| Revenue Next Year | $1.56 | $7.51 |
| P/E Ratio | ★ N/A | $31.30 |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $93.41 | $250.05 |
| 52 Week High | $120.76 | $628.92 |
| Indicator | SJM | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 37.57 |
| Support Level | $105.59 | $418.96 |
| Resistance Level | $112.87 | $470.79 |
| Average True Range (ATR) | 2.96 | 16.57 |
| MACD | -0.93 | 6.04 |
| Stochastic Oscillator | 7.23 | 38.05 |
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (73% of fiscal 2025 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of sweet baked snacks (through the Hostess acquisition) and international (primarily Canada). Retail coffee is its largest category (32% of sales) with brands Folgers and Dunkin'. Pet foods (19% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from frozen handhelds and spreads, through brands Jif, Smucker's, and Uncrustables. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.